series-a
Stage
2
Investors
About
T-CURX develops non-viral CAR-T cell therapies using T cell-targeted lipid nanoparticles to deliver Sleeping Beauty transposon vectors, enabling stable CAR expression in vivo for indications including AML, CLL, and solid tumors.
Explore T-CURX's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.